-
US stocks push higher while gold, silver notch fresh records
-
Deadly clashes in Aleppo as Turkey urges Kurds not to be obstacle to Syria's stability
-
Is the United States after Venezuela's oil?
-
Trump admin halts US offshore wind projects citing 'national security'
-
Right wing urges boycott of iconic Brazilian flip-flops
-
From misfits to MAGA: Nicki Minaj's political whiplash
-
Foster grabs South Africa winner against Angola in AFCON
-
Russia pledges 'full support' for Venezuela against US 'hostilities'
-
Spotify says piracy activists hacked its music catalogue
-
Winter Olympics organisers resolve snow problem at ski site
-
Fuming Denmark summons US ambassador over Greenland envoy
-
UK's street artist Banksy unveils latest mural in London
-
Rugby players lose order challenge in brain injury claim
-
UK singer Chris Rea dies at 74, days before Christmas
-
Last of kidnapped Nigerian pupils handed over, government says
-
Zambia strike late to hold Mali in AFCON opener
-
Outcry follows CBS pulling program on prison key to Trump deportations
-
Sri Lanka cyclone caused $4.1 bn damage: World Bank
-
Billionaire Ellison offers personal guarantee for son's bid for Warner Bros
-
Tech stocks lead Wall Street higher, gold hits fresh record
-
Telefonica to shed around 5,500 jobs in Spain
-
Cambodia says Thailand launches air strikes after ASEAN meet on border clashes
-
McCullum wants to stay as England coach despite Ashes drubbing
-
EU slams China dairy duties as 'unjustified'
-
Italy fines Apple nearly 100 mn euros over app privacy feature
-
America's Cup switches to two-year cycle
-
Jesus could start for Arsenal in League Cup, says Arteta
-
EU to probe Czech aid for two nuclear units
-
Strauss says sacking Stokes and McCullum will not solve England's Ashes woes
-
Clashing Cambodia, Thailand agree to border talks after ASEAN meet
-
Noel takes narrow lead after Alta Badia slalom first run
-
Stocks diverge as rate hopes rise, AI fears ease
-
Man City players face Christmas weigh-in as Guardiola issues 'fatty' warning
-
German Christmas markets hit by flood of fake news
-
Liverpool fear Isak has broken leg: reports
-
West Indies captain says he 'let the team down' in New Zealand Tests
-
Thailand says Cambodia agrees to border talks after ASEAN meet
-
Alleged Bondi shooters conducted 'tactical' training in countryside, Australian police say
-
Swiss court to hear landmark climate case against cement giant
-
Steelers beat Lions in 'chaos' as three NFL teams book playoffs
-
Knicks' Brunson scores 47, Bulls edge Hawks epic
-
Global nuclear arms control under pressure in 2026
-
Five-wicket Duffy prompts West Indies collapse as NZ win series 2-0
-
Asian markets rally with Wall St as rate hopes rise, AI fears ease
-
Jailed Malaysian ex-PM Najib loses bid for house arrest
-
Banned film exposes Hong Kong's censorship trend, director says
-
Duffy, Patel force West Indies collapse as NZ close in on Test series win
-
Australian state pushes tough gun laws, 'terror symbols' ban after shooting
-
A night out on the town during Nigeria's 'Detty December'
-
US in 'pursuit' of third oil tanker in Caribbean: official
IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025
POTOMAC, MARYLAND / ACCESS Newswire / June 27, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that the Company will host a conference call and webcast on Monday, June 30, 2025, at 11:00 a.m. Eastern Time to review the Company's operational progress for the fiscal year ended March 31, 2025. The Company will release its fiscal year 2025 financial results that day before the market opens.
To participate in the call by phone, dial (888) 506 0062 approximately five minutes prior to the scheduled start time. International callers please dial (973) 528 0011. Callers should use access code: 370284.
Investors may access the live webcast via the following link:https://www.webcaster4.com/Webcast/Page/2938/52547
A replay of the teleconference will be available at the above link until July 31, 2025.
About IGC Pharma (dba IGC):
IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With 30 patent filings and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Qs filed with the SEC on August 7, 2024, November 12, 2024, and February 14, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contact Information
Rosalyn Christian/Walter Frank
IMS Investor Relations
[email protected]
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on ACCESS Newswire
A.O.Scott--AT